MaxCyte (MXCT)
(Delayed Data from NSDQ)
$4.10 USD
-0.25 (-5.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.11 +0.01 (0.24%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
MaxCyte, Inc. (MXCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.25 | $11.00 | $7.00 | 112.64% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for MaxCyte, Inc. comes to $9.25. The forecasts range from a low of $7.00 to a high of $11.00. The average price target represents an increase of 112.64% from the last closing price of $4.35.
Analyst Price Targets (4 )
Broker Rating
MaxCyte, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/26/2024 | Craig-Hallum | Matthew G Hewitt | Strong Buy | Strong Buy |
3/13/2024 | Stephens | Jacob Johnson | Strong Buy | Strong Buy |
3/13/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
3/5/2024 | William Blair | Matt Larew | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $9.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.13 |
MXCT FAQs
MaxCyte, Inc. (MXCT) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for MaxCyte, Inc. (MXCT) is $9.25. The current on short-term price targets is based on 3 reports.
The forecasts for MaxCyte, Inc. (MXCT) range from a low of $7 to a high of $11. The average price target represents a increase of $125.61 from the last closing price of $4.10.
The current UPSIDE for MaxCyte, Inc. (MXCT) is 125.61%
Based on short-term price targets offered by four analysts, the average price target for MaxCyte, Inc. comes to $9.25. The forecasts range from a low of $7.00 to a high of $11.00. The average price target represents an increase of 112.64% from the last closing price of $4.35.